ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "juvenile dermatomyositis"

  • Abstract Number: 2469 • 2015 ACR/ARHP Annual Meeting

    The Lymphocyte Repertoire in Juvenile Dermatomyositis

    Lauren A. Henderson1, Edwin Anderson1, Robert C. Fuhlbrigge1,2, Luigi D. Notarangelo1,3,4 and Susan Kim1, 1Division of Immunology, Boston Children's Hospital, Boston, MA, 2Department of Dermatology, Brigham and Women's Hospital, Boston, MA, 3The Manton Center for Orphan Disease Research, Boston Children's Hospital, Boston, MA, 4Harvard Stem Cell Institute, Boston, MA

    Background/Purpose:  In adult dermatomyositis, clonal populations of T lymphocytes with shared variable (V) gene usage have been identified, suggesting aberrant T cell responses to a…
  • Abstract Number: 411 • 2015 ACR/ARHP Annual Meeting

    Patient Reported Outcomes in Juvenile Dermatomyositis: Assessing the Importance of Different Measures to Patients and Families

    Heather Tory1, Ruy Carrasco2, Thomas Griffin3, Melissa M. Hazen4, Adam M. Huber5, Philip Kahn6, Angela Byun Robinson7, Susan Kim8 and The Childhood Arthritis and Rheumatology Research Alliance Juvenile Dermatomyositis Quality Measures Workgroup, 1Rheumatology, Connecticut Children's Medical Center, Hartford, CT, 2Pediatric Rheumatology, Specially For Children, Austin, TX, 3Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 4Rheumatology, Children's Hospital Boston, Boston, MA, 5Pediatric rheumatology, IWK Health Centre, Halifax, NS, Canada, 6Pediatric Rheumatology, New York University, New York, NY, 7Pediatrics, Rainbow Babies & Children's Hospital / Case Medical Center, Cleveland, OH, 8Division of Immunology, Boston Children's Hospital, Boston, MA

    Background/Purpose: Patient reported outcomes (PROs) are becoming increasingly important in the care of patients with chronic disease. Involving patients in their own care significantly improves…
  • Abstract Number: 2900 • 2014 ACR/ARHP Annual Meeting

    Clinically Inactive Disease in Juvenile Dermatomyositis – a Proposed Revision to the Pediatric Rheumatology International Trials Organisation Criteria

    Beverley Almeida1, Raquel Campanilho-Marques2, Katie Arnold2, Lucy R. Wedderburn3,4, Clarissa A Pilkington5 and Kiran Nistala6, 1Department of Rheumatology, Great Ormond Street Hospital for Children NHS Trust, London, United Kingdom, 2Infection, Inflammation and Rheumatology Section, UCL Institute for Child Health, London, United Kingdom, 3Institute of Child Health, University College London, London, United Kingdom, 4Arthritis Research UK Centre for Adolescent Rheumatology,, UCL, UCLH, GOSH NHS Trust, London, United Kingdom, 5Rheumatology, Great Ormond Street Hospital for Children NHS Trust, London, United Kingdom, 6Centre for Rheumatology, University College London, London, United Kingdom

    Background/Purpose: Juvenile dermatomyositis (JDM) affects 3 children/million/year with myositis and skin disease being the typical features. The Pediatric Rheumatology International Trials Organisation (PRINTO) have recently…
  • Abstract Number: 2211 • 2014 ACR/ARHP Annual Meeting

    Epidemiologic and Clinical Features of Patients with Adult and Juvenile Dermatomyositis, Polymyositis and Inclusion Body Myositis from Myovision, a National Myositis Patient Registry

    Abdullah Faiq1, Payam Noroozi Farhadi1, Nastaran Bayat1, Mikaela Chase1, Anna Jansen1, Karen Malley2, Jesse Wilkerson3, Kathryn Rose4, Caroll Co4, Lukasz Itert5, Anne Johnson6, Richard Morris4, Christine Parks7, Edward H. Giannini8, Hermine I. Brunner8, Frederick W. Miller1, Bob Goldberg9 and Lisa G. Rider1, 1Environmental Autoimmunity Group, NIEHS, NIH, Bethesda, MD, 2Malley Research Programming, Inc, Bethesda, MD, 3Social and Scientific Systems, Inc., Research Triangle Park, NC, 4Social and Scientific Systems, Inc., Durham, NC, 5Division of Pediatric Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 6Pediatric Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 7Epidemiology Branch, NIEHS, NIH, Research Triangle Park, NC, 8Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 9The Myositis Association, Alexandria, VA

    Background/Purpose: The myositis syndromes are rare systemic autoimmune diseases, little is known about their epidemiology.  We describe the demographics and comorbidities of patients in a…
  • Abstract Number: 2222 • 2014 ACR/ARHP Annual Meeting

    Predictors of Myositis Treatments Received and Associated Treatment Responses in Myovision, a National Myositis Patient Registry

    Abdullah Faiq1, Payam Noroozi Farhadi1, Jesse Wilkerson2, Nastaran Bayat1, Anna Jansen3, Kathryn Rose4, Lukasz Itert5, Anne Johnson6, Christine Parks7, Edward H. Giannini8, Hermine I. Brunner9, Bob Goldberg10, Richard Morris4, Frederick W. Miller1 and Lisa G. Rider1, 1Environmental Autoimmunity Group, NIEHS, NIH, Bethesda, MD, 2Social and Scientific Systems, Inc., Research Triangle Park, NC, 3Environmental Autoimmunity Group, NIEHS / EAG, Bethesda, MD, 4Social and Scientific Systems, Inc., Durham, NC, 5Division of Pediatric Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 6Pediatric Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 7Epidemiology Branch, NIEHS, NIH, Research Triangle Park, NC, 8Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 9PRCSG, Cincinnati, OH, 10The Myositis Association, Alexandria, VA

    Background/Purpose: Little is known about medications received for myositis and patients’ responses to therapies. We present information on self-reported myositis therapy use and responses from…
  • Abstract Number: 1317 • 2014 ACR/ARHP Annual Meeting

    Anti-p155/140 Autoantibodies and Selected Features at Illness Onset Are Associated with a Chronic Course of Illness in the Juvenile Idiopathic Inflammatory Myopathies

    G. Esther A. Habers1, Adam M. Huber2, Gulnara Mamyrova3, Ira Targoff4, Chantal Boonacker5, Marco van Brussel1, Frederick W. Miller6, Lisa G. Rider6 and Annet van Royen-Kerkhof7, 1Child Development and Exercise Center, Wilhelmina Children's Hospital, University Medical Center Utrecht, Utrecht, Netherlands, 2IWK Health Centre, Halifax, NS, Canada, 3Rheumatology, George Washington University, Washington, DC, 4Oklahoma Medical Research Foundation, Oklahoma City, OK, 5Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, Netherlands, 6Environmental Autoimmunity Group, NIEHS, NIH, Bethesda, MD, 7Paediatric Immunology and Rheumatology, University Medical Centre Utrecht - Wilhelmina Children's Hospital, Utrecht, Netherlands

    Background/Purpose : Three types of disease courses can be distinguished in patients with juvenile idiopathic inflammatory myopathies (JIIM), namely monocyclic (M), polycyclic (P), and chronic…
  • Abstract Number: 1981 • 2013 ACR/ARHP Annual Meeting

    Developing International Consensus Definitions Of Improvement For Adult and Juvenile Dermatomyositis and Polymyositis

    Saad Feroz1, Nicolino. Ruperto2, Jiri Vencovsky3, Peter A. Lachenbruch1, Brian Erman4, Adam Huber5, Brian M. Feldman6, Ingrid E. Lundberg7, Angela Pistorio8, Howard Rockette9, Frederick W. Miller1, Rohit Aggarwal10, Lisa G. Rider1, for The ACR-EULAR Myositis Response Criteria Project Group11, Angelo Ravelli12, Clarissa Pilkington13 and Sheila K. Oliveira14, 1Environmental Autoimmunity Group, NIEHS, NIH, Bethesda, MD, 2PRINTO, IRCCS G. Gaslini, Genoa, Italy, 3Institute of Rheumatology, Department of Clinical and Experimental Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, 4SRA International, Research Triangle Park, NC, 5IWK Health Centre, Halifax, NS, Canada, 6Rheumatology, Hospital for Sick Children, Toronto, ON, Canada, 7Rheumatology Unit, Karolinska University Hospital, Solna, Karolinska Institutet, Stockholm, Sweden, 8PRINTO, Genoa, Italy, 9University of Pittsburgh, Pittsburgh, PA, 10Medicine / Rheumatology, University of Pittsburgh, Pittsburgh, PA, 11NIEHS, NIH, Bethesda, MD, 12Paediatric Rheumatology International Trials Organization (PRINTO), Istituto Giannina Gaslini, Genova, Italy, 13Rheumatology Department, Great Ormond Street Hospital, London, United Kingdom, 14Pediatric Rheumatology, Instituto de Pediatria e Puericultura Martagão Gesteira (IPPMG) da Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro, Brazil

    Background/Purpose: IMACS and PRINTO have developed preliminary core set activity measures and definitions of improvement (DOIs). However, these were developed from small and partially retrospective…
  • Abstract Number: 2473 • 2012 ACR/ARHP Annual Meeting

    A Randomized Trial in New Onset Juvenile Dermatomyositis: Prednisone Versus Prednisone Plus Cyclosporine Versus Prednisone Plus Methotrexate

    Nicolino Ruperto1, Angela Pistorio2, Sheila Oliveira3, Rubén J. Cuttica4, Angelo Ravelli1, Michel Fischbach5, Stefan Hagelberg1, Tadej Avcin6, Emanuel Cheuret1, Fabrizia Corona7, Gerard Couillault1, Frank Dressler1, Valeria Gerloni1, Gary Sterba Sr.1, Francesco Zulian1, Maria Teresa Apaz1, Adriana Cespedes-Cruz1, Rolando Cimaz1, Fabrizio De Benedetti8, Pierre Quartier1, Ricardo Russo1, Nico Wulffraat1, Simona Angioloni1 and Alberto Martini9, 1Paediatric Rheumatology International Trials Organization (PRINTO), Istituto Giannina Gaslini, Genova, Italy, 2PRINTO, Genoa, Italy, 3Istituto Giannina Gaslini, Pediatria II, Reumatologia, Paediatric Rheumatology International Trials Organisation (PRINTO) Coordinating Center, Genoa, Italy, Genova, Italy, 4Hospital de Niños Pedro de Elizalde - University of Buenos Aires, Buenes Aires, Argentina, 5Pediatric Rheumatology International Trials Organization (PRINTO)-Istituto Gaslini, Genova, Italy, 6The Ljubljana University Medical Centre, Pediatric Clinic, Ljubljana, Slovenia, 7Reumatologia Pediatrica, Paediatric Department University of Milano, Milano, Italy, 8IRCCS Ospedale Pediatrico Bambino Gesú, Rome, Italy, 9Pediatric Rheumatology Collaborative Study Group [PRSCG], Cincinnati, OH

    Background/Purpose: Data regarding the safety and efficacy of treatment regimens for juvenile dermatomyositis(JDM) tends to be from anecdotal, small, uncontrolled, non-randomized case series. This randomized…
  • Abstract Number: 1935 • 2012 ACR/ARHP Annual Meeting

    Longitudinal Peripheral Blood Lymphocyte Subsets Correlate with Decreased Disease Activity in Juvenile Dermatomyositis

    Floranne C. Ernste1, Cynthia S. Crowson2, Consuelo Lopez de Padilla3, Molly Hein4, Abigail B. Green2 and Ann M. Reed5, 1Division of Rheumatology, Mayo Clinic Rochester, Rochester, MN, 2Department of Health Sciences Research, Mayo Clinic, Rochester, MN, 3Rheumatology/Immunology Research, Mayo Clinic, Rochester, MN, 4Mayo Clinic, Rochester, MN, 5Rheumatology, Mayo Clinic, Rochester, MN

    Background/Purpose: Perturbations in peripheral blood lymphocyte (PBL) subsets in juvenile dermatomyositis (JDM) are variably and inconsistently reported in active and inactive disease. Decreased PBL CD8+…
  • Abstract Number: 1037 • 2012 ACR/ARHP Annual Meeting

    Magnetic Resonance Imaging (MRI) Assessment of Inflammatory Myopathy: Quantitative Fat-Corrected Muscle T2 and Conventional T2 Measurement Versus Standard MRI and Clinical Metrics

    Lawrence Yao1, Adrienne L. Yip2, Sepehr Mesdaghinia2, Ashkan Shademan2, Joseph A. Shrader3, Anna V. Jansen4, Frederick W. Miller4 and Lisa G. Rider4, 1Diagnostic Radiology, NIH Clinical Center, Bethesda, MD, 2NIEHS, NIH, Bethesda, MD, 3Rehabilitation Medicine, Clinical Center, NIH, Bethesda, MD, 4Environmental Autoimmunity Group, NIEHS, NIH, Bethesda, MD

    Background/Purpose: Active muscle disease in patients with idiopathic inflammatory myopathies (IIM) is characterized by prolonged muscle T2 relaxation on MRI. We examined the utility of…
  • Abstract Number: 291 • 2012 ACR/ARHP Annual Meeting

    Illness Features Associated with an Increased Risk of Mortality in Children with Juvenile Idiopathic Inflammatory Myopathies

    Adam M. Huber1, Gulnara Mamyrova2, Julia A. Lee3, Peter A. Lachenbruch4, Ira N. Targoff5, Frederick W. Miller4, Lisa G. Rider4 and Childhood Myositis Heterogeneity Study Group6, 1Dalhousie University, Halifax, NS, Canada, 2Rheumatology, George Washington University, Washington, DC, 3Environmental Autoimmunity Grp, NIEHS, Bethesda, MD, 4Environmental Autoimmunity Group, NIEHS, NIH, Bethesda, MD, 5Arthritis and Immunology, Oklahoma Medical Research Foun, Oklahoma City, OK, 6Bethesda, MD

    Background/Purpose: Juvenile idiopathic inflammatory myopathies (JIIM) are potentially life-threatening systemic autoimmune diseases but little in known regarding factors associated with mortality. Methods: Patients enrolled in…
  • Abstract Number: 207 • 2012 ACR/ARHP Annual Meeting

    Interferon-Driven Chemokines Are Associated with Changes in Disease Activity Among Rituximab-Treated Refractory Myositis  Patients with Pulmonary Involvement – the RIM Study

    Cynthia S. Crowson1, Ann M. Reed2, Molly Hein3, Abigail B. Green1, Consuelo Lopez de Padilla4, Rohit Aggarwal5, Dana P. Ascherman6, Marc C. Levesque7 and Chester V. Oddis8, 1Department of Health Sciences Research, Mayo Clinic, Rochester, MN, 2Rheumatology, Mayo Clinic, Rochester, MN, 3Mayo Clinic, Rochester, MN, 4Rheumatology/Immunology Research, Mayo Clinic, Rochester, MN, 5Medicine, University of Pittsburgh, Pittsburgh, PA, 6Medicine/Rheumatology, University of Miami, Miami, FL, 7Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, 8Rheum/Clinical Immunology, University of Pittsburgh, Pittsburgh, PA

    Background/Purpose: The Rituximab in Myositis (RIM) Study provides a unique resource for biomarker investigation of homogeneously treated refractory adult and juvenile myositis patients. Building on…
  • Abstract Number: 206 • 2012 ACR/ARHP Annual Meeting

    Clinical, Laboratory, and Cellular Responses in the Rituximab in Myositis Trial in Patients Enrolled At the National Institutes of Health

    Lisa G. Rider1, Adrienne L. Yip2, Iren Horkayne-Szakaly3, Rita Volochayev2, Joseph A. Shrader4, Maria L. Turner5, Heidi H. Kong5, Minal S. Jain4, Anna V. Jansen1, Chester V. Oddis6, Thomas A. Fleisher7 and Frederick W. Miller1, 1Environmental Autoimmunity Group, National Institute of Environmental Health Sciences, National Institutes of Health, Bethesda, MD, 2National Institute of Environmental Health Sciences, National Institutes of Health, Bethesda, MD, 3Joint Pathology Center, Silver Spring, MD, 4Rehabilitation Medicine, Rehab Medicine, NIH Clinical Center, Bethesda, MD, 5Dermatology Branch, Center for Cancer Research, NCI, NIH, Bethesda, MD, 6Rheum/Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, 7Laboratory Medicine, Laboratory Medicine, NIH Clinical Center, Bethesda, MD

    Background/Purpose: To assess changes in myositis core set measures, clinical and laboratory data, and paired muscle biopsies from NIH patients enrolled in the Rituximab in…
  • « Previous Page
  • 1
  • …
  • 3
  • 4
  • 5
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology